Author
Listed:
- Hsing-Wei Hung
(Department of Nursing, Chang Gung Memorial Hospital at Linkou, Taoyuan 333, Taiwan
School of Nursing, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan)
- Chien-Ying Liu
(Division of Thoracic Oncology, Department of Thoracic Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan 333, Taiwan
Thoracic Oncology Unit, Cancer Center, Chang Gung Memorial Hospital at Linkou, Taoyuan 333, Taiwan
Department of Medicine, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan)
- Hsiu-Fang Chen
(Department of Nursing, Chang Gung Memorial Hospital at Linkou, Taoyuan 333, Taiwan
Department of Nursing, College of Nursing, Chang Gung University of Science and Technology, Taoyuan 333, Taiwan)
- Chun-Chu Chang
(Department of Nursing, Chang Gung Memorial Hospital at Linkou, Taoyuan 333, Taiwan
Department of Nursing, College of Nursing, Chang Gung University of Science and Technology, Taoyuan 333, Taiwan)
- Shu-Ching Chen
(School of Nursing, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan
School of Nursing and Geriatric and Long-Term Care Research Center, College of Nursing, Chang Gung University of Science and Technology, Taoyuan 333, Taiwan
Department of Radiation Oncology and Proton and Radiation Therapy Center, Linkou Chang Gung Memorial Hospital, Taoyuan 333, Taiwan)
Abstract
Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect of neurotoxic anticancer drugs that may affect quality of life (QoL). Purpose: The purposes of this study were to: assess the levels of CIPN, anxiety, depression, CIPN–related QoL, and general QoL; and identify the factors related to CIPN–related QoL and general QoL in patients with advanced lung cancer (LC) receiving platinum-based chemotherapy. This cross-sectional study examined patients with advanced LC who received platinum-based chemotherapy from the thoracic oncology inpatient wards of a medical center in northern Taiwan. Structured questionnaires were used to measure patients’ CIPN (European Organization for Research and Treatment of Cancer quality of life questionnaire–chemotherapy–induced peripheral neuropathy 20), anxiety (Hospital Anxiety and Depression Scale Depression Scale [HADS]), depression (HADS), CIPN-related QoL (Functional Assessment of Cancer Therapy /Gynecologic Oncology Group-Neurotoxicity subscale [FACT/GOG–Ntx]), and general QoL (Functional Assessment of Cancer Therapy–General Input [FACT-G]). Of 93 patients with advanced LC, 53.8% reported CIPN–sensory impairment and 47.3% reported CIPN–motor impairment. The most common CIPN symptoms were difficulty getting or maintaining an erection (only for men > 65 years) and difficulty in climbing stairs or getting up out of a chair. Poor CIPN–related QoL (FACT/GOG–Ntx) was associated with more CIPN–sensory and more CIPN–motor impairment. Poor general QoL (FACT-G) was associated with a higher level of depression, a higher level of anxiety, and receipt of more chemotherapy cycles. More than half of LC patients report impairment related to CIPN, calling for holistic treatment to improve QoL.
Suggested Citation
Hsing-Wei Hung & Chien-Ying Liu & Hsiu-Fang Chen & Chun-Chu Chang & Shu-Ching Chen, 2021.
"Impact of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-Based Chemotherapy,"
IJERPH, MDPI, vol. 18(11), pages 1-12, May.
Handle:
RePEc:gam:jijerp:v:18:y:2021:i:11:p:5677-:d:562232
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:18:y:2021:i:11:p:5677-:d:562232. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.